Clinical Trial Update: A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase Ib trial evaluating the safety and activity of neoadjuvant tislelizumab plus the FLOT chemotherapy regimen in patients with resectable esophagogastric ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophagogastric Junction Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DOCETAXEL (DOCETAXEL)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Status: RECRUITING